Stocks in Focus: Star Health, Bandhan Bank Reach 52-Week High, Ceat Shares Surge 8% on Earnings Strength

Market Activity Drives Stocks Amid Earnings Season

April 28 marked a significant day in the market as corporate developments, earnings updates, and regulatory triggers fueled activity among several stocks.

Star Health and Allied Insurance Company shares experienced a notable surge, rising 9 percent to hit a 52-week high of Rs 586.75. The insurer's Q4 profit saw a remarkable turnaround, increasing over 218 times to ₹111.3 crore from ₹0.51 crore a year ago. Additionally, the company reported steady operational growth, with net premium earned rising 13.9% to ₹4,327.2 crore, while net commission income increased 4.3% to ₹792.6 crore.

In the banking sector, Bandhan Bank share price rose 9 percent following a solid performance, with Q4 profit jumping 68% year-on-year to ₹534.1 crore. However, growth in core income remained modest, as net interest income edged up 1.4% to ₹2,795.6 crore.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

CEAT share price advanced 8 percent after the company reported a sharp 145.1% rise in consolidated profit to ₹243.85 crore, driven by robust demand, while revenue climbed 23.3% to ₹4,218.9 crore. Similarly, Motherson Sumi Wiring India share price gained as the company's Q4 saw revenue surge 32.9% to ₹3,334.6 crore, though profit growth remained muted at 1.4%, indicating margin pressures.

Meanwhile, Greenply Industries shares rose 12 percent on reporting an 86.4% jump in Q4 profit to ₹30.7 crore and revenue increasing 19.6% to ₹776.2 crore.

Solara Active Pharma Sciences share price added more than 3 percent after the company received a positive update as its Ibuprofen manufacturing facility in Puducherry successfully cleared an unannounced inspection by the U.S. Food and Drug Administration. The facility was classified under Voluntary Action Indicated (VAI), with the inspection now formally closed.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Dr Reddys Laboratories share price lost 1 percent despite receiving Health Canada approval for Ozempic.

Market participants noted that news flow remains a key driver in the current environment, with investors closely tracking corporate announcements and sector-specific triggers. With earnings season in progress, company-specific updates are expected to drive further volatility.